tradingkey.logo
tradingkey.logo
Search

Amgen Inc

AMGN
Add to Watchlist
374.150USD
+12.820+3.55%
Close 07/02, 13:00ETQuotes delayed by 15 min
201.59BMarket Cap
25.83P/E TTM

TradingKey Stock Score of Amgen Inc

Currency: USD Updated: 2026-07-01

Key Insights

Amgen Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 361.78.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Amgen Inc's Score

Industry at a Glance

Industry Ranking
26 / 157
Overall Ranking
75 / 4564
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

47°C

Very Low
Very High
Negative

Amgen Inc Highlights

StrengthsRisks
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.37% year-on-year.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 120.56%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 120.56%.
Fairly Valued
The company’s latest PE is 24.94, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 460.83M shares, increasing 0.49% quarter-over-quarter.
Held by Bill Smead
Star Investor Bill Smead holds 725.23K shares of this stock.

Analyst Rating

Based on 37 analysts
Hold
Current Rating
361.782
Target Price
+0.34%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Amgen Inc?

The TradingKey Stock Score provides a comprehensive assessment of Amgen Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Amgen Inc’s performance and outlook.

How do we generate the financial health score of Amgen Inc?

To generate the financial health score of Amgen Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Amgen Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Amgen Inc.

How do we generate the company valuation score of Amgen Inc?

To generate the company valuation score of Amgen Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Amgen Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Amgen Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Amgen Inc.

How do we generate the earnings forecast score of Amgen Inc?

To calculate the earnings forecast score of Amgen Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Amgen Inc’s future.

How do we generate the price momentum score of Amgen Inc?

When generating the price momentum score for Amgen Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Amgen Inc’s prices. A higher score indicates a more stable short-term price trend for Amgen Inc.

How do we generate the institutional confidence score of Amgen Inc?

To generate the institutional confidence score of Amgen Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Amgen Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Amgen Inc.

How do we generate the risk management score of Amgen Inc?

To assess the risk management score of Amgen Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Amgen Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Amgen Inc.